MEDICORTEX-FINLAND-OY
15.4.2021 08:27:09 CEST | Business Wire | Press release
Medicortex Finland Oy, a biotechnology company developing a breakthrough biomarker-based diagnostic kit for brain injury detection, completed collection of body fluid samples in its third large clinical study. Children and adolescents were recruited who visited the hospital with a suspected mild traumatic brain injury or concussion.
"Collecting the samples in this large clinical trial is a significant achievement for Medicortex, and represents an important step forward in the development of the ProbTBITM , a diagnostic kit for early detection of head injury" said Dr. Adrian Harel, Chief Executive Officer of Medicortex Finland. "Brain injury is a devastating condition leading to medical complications if not diagnosed. We have the opportunity to develop a portable non-invasive test for quick detection of mild traumatic brain injury (TBI) and concussion, and thereby help young patients and families who so desperately need it.” Dr. Harel added.
In the current clinical study Medicortex collected body fluid samples from total of 58 subjects, consisting of patients with head injury and uninjured healthy volunteers of matching age. A Finnish central hospital Satasairaala in Pori served as the study site recruiting the study subjects and collecting the body fluid samples. The next step is to analyze the samples for the presence and level of the unique biomarker and to demonstrate statistical difference between the patients with TBI and healthy control subjects. “The biomarker we are targeting has never before been used for mild brain injury detection. The fact that we can readily find it in easily accessible body fluids such as urine and saliva enable us to develop a user-friendly diagnostic kit for concussion and mild TBI detection”, says Dr. Harel.
Medicortex is working towards the validation of a traumatic brain injury (TBI) biomarker and incorporating it into a quick and reliable diagnostic kit that can be easily used by the first responders and healthcare professionals.
As Mediortex reaches this important milestone, preparations are underway for an Initial Public Offering and a listing of the company’s shares on a stock exchange. Medicortex is currently accepting subscription commitments in an ongoing Private Placement (pre-IPO) which will equip Medicortex with the necessary resources to ambitiously further developments and strengthen the company for its planned IPO. To read more about the investment case, please visit the Medicortex website (www.medicortex.fi/investors ).
About Medicortex
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect head injuries in an easy way. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Once the company completes the biomarker development its next goal will be to develop an innovative drug to halt the progression of brain injury. Medicortex was founded by an Israeli neurobiologist Adrian Harel (Ph.D., MBA) and the company is based in Turku, Finland.
Key words: NFL, ice-hockey, rugby, brain injury, head injury, concussion, diagnostics, TBI, sport, professional athletes, boxing, early detection, trauma, clinical trial
Forward-Looking Statements
This press release contains statements that are “forward-looking statements” that are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414006023/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 07:10:00 CEST | Press release
2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment effec
Pure Lithium Receives Australian Patent for "Lithium Metal Anode and Battery"6.8.2026 22:49:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated next-generation lithium metal battery technology company, today announced that the Australian patent office has granted the company a patent (AU2025271196) titled “Lithium metal anode and battery.” Australia mines roughly half of the world’s lithium, yet has no domestic battery production at all; every battery the country uses is imported. The granted patent is directed to ways in which Pure Lithium’s technology can change that. Rather than trying to catch up in lithium-ion, Australia can leapfrog the incumbent technology and establish a next-generation industry. As worldwide demand for batteries grows, every country capable of making batteries needs to be making them. That is Pure Lithium’s central goal: opening up markets around the world through battery technology that enables local, independent supply chains, keeping pace with demand and strengthening economies. China controls the lithium-ion battery supply chain and manufactures th
Vercel Appoints Amit Agarwal, Standard Template Labs CEO and former Datadog President, to Board of Directors6.8.2026 17:00:00 CEST | Press release
The product leader who helped scale Datadog from early-stage startup through IPO brings deep product expertise to Vercel's board Vercel, the agentic infrastructure company, today announced the appointment of Amit Agarwal, former president of Datadog and founder and CEO of Standard Template Labs, an AI-first service management platform, to its board of directors. Agarwal brings 25 years of enterprise software experience and a track record of scaling a product-led company from its earliest days into one of the defining public software companies of the cloud era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806738617/en/ Amit Agarwal Agarwal joined Datadog in 2012 as its Chief Product Officer and was named President in 2022, overseeing product, corporate development, and go-to-market functions as the company grew past $2.5 billion in annual revenue. Across 13 years, including Datadog's 2019 IPO and its first years as a pub
Laserfiche Launches Advanced Enterprise Security to Deliver Multi-Region Disaster Recovery and GovRAMP-Ready Compliance for Highly Regulated Industries6.8.2026 16:00:00 CEST | Press release
New security suite extends Laserfiche’s proven security controls and adds near real-time data replication for governments, law enforcement and security-conscious enterprises. Laserfiche — the leading SaaS provider of intelligent content management — today announced the launch of Enterprise Security, an advanced suite of security enhancements designed for organizations navigating complex regulatory environments. Enterprise Security addresses GovRAMP and CJIS (Criminal Justice Information Services) security requirements based on the NIST SP 800-53 framework. For organizations handling privileged citizen, legal or corporate data, these built-in controls streamline audit preparation and fortify defenses. With organizations placing a higher priority on data stewardship and corporate governance, enterprise IT leaders require a security architecture that protects data without slowing down operations. Laserfiche Enterprise Security extends Laserfiche Cloud’s highly resilient infrastructure wit
AM Best Upgrades Fortegra Insurance Subsidiaries to A (Excellent)6.8.2026 15:00:00 CEST | Press release
Rating actions follow completion of the DB Insurance acquisition The Fortegra Group, Inc. (“Fortegra” or the “Company”), a global specialty insurer and part of DB Insurance Co., Ltd., today announced that AM Best has upgraded the Financial Strength Rating (FSR) of its insurance subsidiaries to A (Excellent) from A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) to “a” (Excellent) from “a-” (Excellent). The outlook assigned to the ratings is stable, and AM Best removed the ratings from under review with positive implications. KBRA has also upgraded all of its ratings for the Company. The upgrade applies across Fortegra’s insurance platform. The property and casualty companies include Lyndon Southern Insurance Company, Insurance Company of the South, Response Indemnity Company of California, Blue Ridge Indemnity Company, Fortegra Specialty Insurance Company and Fortegra Europe Insurance Company SE. The life and health companies include Life of the South Insurance Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom